Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Chinese (SSE) Clinical Research and Equipment Industry Analysis

UpdatedMay 24, 2026
DataAggregated Company Financials
Companies27
  • 7D-0.2%
  • 3M-4.2%
  • 1Y39.5%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has risen 1.1%, driven by gains from WuXi AppTec of 0.8%. In the same time, Hangzhou Tigermed Consulting was down 9.5%. This means that the industry has gained 42% over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 24 May 2026CN¥583.5bCN¥98.7bCN¥21.7b60.2x26.9x5.9x
Tue, 21 Apr 2026CN¥594.3bCN¥95.0bCN¥20.7b65.4x28.7x6.3x
Thu, 19 Mar 2026CN¥550.9bCN¥94.5bCN¥18.7b60.6x29.5x5.8x
Sat, 14 Feb 2026CN¥607.6bCN¥94.4bCN¥18.6b68.1x32.7x6.4x
Mon, 12 Jan 2026CN¥618.4bCN¥94.3bCN¥18.5b63.8x33.4x6.6x
Wed, 10 Dec 2025CN¥549.3bCN¥94.3bCN¥18.5b63.5x29.6x5.8x
Fri, 07 Nov 2025CN¥579.3bCN¥93.5bCN¥18.8b64.3x30.8x6.2x
Sun, 05 Oct 2025CN¥640.5bCN¥92.1bCN¥17.4b70.8x36.7x7x
Tue, 02 Sep 2025CN¥636.7bCN¥92.6bCN¥17.6b61.9x36.1x6.9x
Thu, 31 Jul 2025CN¥588.2bCN¥91.7bCN¥17.9b61.5x32.8x6.4x
Sat, 28 Jun 2025CN¥424.5bCN¥89.8bCN¥15.4b47.4x27.6x4.7x
Mon, 26 May 2025CN¥402.3bCN¥89.1bCN¥15.3b42.8x26.3x4.5x
Wed, 23 Apr 2025CN¥374.9bCN¥88.5bCN¥14.0b38.4x26.8x4.2x
Fri, 21 Mar 2025CN¥454.3bCN¥89.7bCN¥12.7b43.7x35.7x5.1x
Sun, 16 Feb 2025CN¥411.8bCN¥88.1bCN¥11.2b42x36.6x4.7x
Tue, 14 Jan 2025CN¥349.9bCN¥86.9bCN¥11.1b32x31.5x4x
Thu, 12 Dec 2024CN¥401.3bCN¥87.8bCN¥11.2b41.7x35.9x4.6x
Sat, 09 Nov 2024CN¥397.3bCN¥87.8bCN¥11.2b41.7x35.5x4.5x
Mon, 07 Oct 2024CN¥386.6bCN¥88.2bCN¥12.4b35.3x31.2x4.4x
Wed, 04 Sep 2024CN¥275.0bCN¥87.1bCN¥12.3b27.6x22.4x3.2x
Fri, 02 Aug 2024CN¥295.8bCN¥87.7bCN¥12.5b26.7x23.6x3.4x
Sun, 30 Jun 2024CN¥279.1bCN¥88.3bCN¥13.4b24.7x20.8x3.2x
Tue, 28 May 2024CN¥313.4bCN¥88.3bCN¥13.4b28.3x23.4x3.5x
Thu, 25 Apr 2024CN¥307.6bCN¥90.5bCN¥15.0b29.9x20.5x3.4x
Sat, 23 Mar 2024CN¥345.2bCN¥90.4bCN¥15.6b33.9x22.1x3.8x
Mon, 19 Feb 2024CN¥346.7bCN¥91.1bCN¥16.1b29.9x21.6x3.8x
Wed, 17 Jan 2024CN¥458.5bCN¥91.1bCN¥16.1b36.6x28.5x5x
Fri, 15 Dec 2023CN¥481.5bCN¥91.1bCN¥16.1b37.1x29.9x5.3x
Sun, 12 Nov 2023CN¥558.5bCN¥91.1bCN¥16.1b40.5x34.7x6.1x
Tue, 10 Oct 2023CN¥517.9bCN¥92.0bCN¥18.3b35.4x28.2x5.6x
Thu, 07 Sep 2023CN¥477.5bCN¥91.8bCN¥18.3b33.5x26.1x5.2x
Sat, 05 Aug 2023CN¥495.8bCN¥91.8bCN¥18.5b35.6x26.8x5.4x
Mon, 03 Jul 2023CN¥448.5bCN¥91.3bCN¥18.5b34.3x24.3x4.9x
Wed, 31 May 2023CN¥490.8bCN¥91.3bCN¥18.5b37.9x26.6x5.4x
Price to Earnings Ratio

26.6x


Total Market Cap: CN¥490.8bTotal Earnings: CN¥18.5bTotal Revenue: CN¥91.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Clinical Research and Equipment Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Chinese Life Sciences Tools and Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 28.7x.
  • The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 6.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 5.6% per year over the last three years.
  • Revenues for these companies have grown 2.6% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?

CN Market-0.042%
Healthcare-2.82%
Life Sciences-0.21%
Clinical Research and Equipment-0.21%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
603259 WuXi AppTecCN¥103.980.8%
+CN¥2.5b		67.6%PE16.5x
603127 Joinn Laboratories(China)Co.LtdCN¥41.353.5%
+CN¥1.0b		139.0%PE61.3x
688131 Shanghai Haoyuan ChemexpressCN¥75.626.6%
+CN¥996.9m		94.0%PE65.4x
688222 HitGenCN¥31.605.7%
+CN¥679.1m		94.3%PE99.2x
603108 Shanghai Runda Medical TechnologyCN¥14.298.0%
+CN¥639.9m		-19.3%PS1.3x

Latest News

688114
CN¥53.13
MGI Tech
7D
1.4%
1Y
-27.8%
300759
CN¥25.93
Pharmaron Beijing
7D
-2.5%
1Y
11.7%
688068
CN¥84.50
Beijing Hotgen Biotech
7D
-11.4%
1Y
-32.5%
603259
CN¥103.98
WuXi AppTec
7D
0.8%
1Y
67.6%
Narrative Update • May 18

603259: Conviction List Inclusion Will Support Confidence In 2026 Guidance

Analysts have lifted their price target on WuXi AppTec to CN¥124.40, supported by a lower discount rate, slightly adjusted growth and margin assumptions, and a reduced future P/E multiple that still keeps the stock on key conviction lists. Analyst Commentary Recent commentary on WuXi AppTec sits against the backdrop of a refreshed price target of CN¥124.40, with major firms such as Goldman Sachs keeping the stock on key conviction lists, even as some investors weigh execution and valuation risks.
300347
CN¥42.32
Hangzhou Tigermed Consulting
7D
-9.5%
1Y
-11.1%
603127
CN¥41.35
Joinn Laboratories(China)Co.Ltd
7D
3.5%
1Y
139.0%
301096
CN¥64.60
Hangzhou Bio-Sincerity Pharma-TechLtd
7D
1.4%
1Y
74.1%
688046
CN¥20.90
GemPharmatech
7D
-2.8%
1Y
80.2%
688222
CN¥31.60
HitGen
7D
5.7%
1Y
94.3%
300463
CN¥9.85
Maccura BiotechnologyLtd
7D
-4.7%
1Y
-16.2%
603108
CN¥14.29
Shanghai Runda Medical Technology
7D
8.0%
1Y
-19.3%
301333
CN¥53.30
R&G PharmaStudies
7D
-7.3%
1Y
9.9%
688131
CN¥75.62
Shanghai Haoyuan Chemexpress
7D
6.6%
1Y
94.0%
688315
CN¥14.74
Novogene
7D
-2.1%
1Y
8.2%
688202
CN¥64.25
Shanghai Medicilon
7D
-2.6%
1Y
107.9%
688758
CN¥19.99
Suzhou Sepax Technologies
7D
1.7%
1Y
22.6%